Design and optimization of an IgG human ELISA assay reactive to recombinant RBD SARS-CoV-2 protein

Abstract

Serology assays are essential tools to mitigate the effect of COVID-19, help to identify previous SARS-CoV-2 infections or vaccination, and provide data for surveillance and epidemiologic studies. In this study, we report the production and purification process of the receptor-binding domain (RBD) of SARS-CoV-2 in HEK293 cells, which allowed the design, optimization, and validation of an indirect ELISA (iELISA) for the detection of human anti-RBD antibodies. To find the optimal conditions of this iELISA, a multivariate strategy was performed throughout design of experiments (DoE) and response surface methodology (RSM), one of the main tools of quality by design (QbD) approach. The adoption of this strategy helped to reduce the time and cost during the method development stage and to define an optimum condition within the analyzed design region. The assay was then validated, exhibiting a sensitivity of 94.24 (86.01–98.42%; 95% CI) and a specificity of 95.96% (89.98–98.89%; 95% CI). Besides, the degree of agreement between quality results assessed using kappa’s value was 0.92. Hence, this iELISA represents a high-throughput technique, simple to perform, reliable, and feasible to be scaled up to satisfy the current demands. Since RBD is proposed as the coating antigen, the intended use of this iELISA is not only the detection of previous exposure to the virus, but also the possibility of detecting protective immunity. Key points • RBD was produced in 1-L bioreactor and highly purified. • An iELISA assay was optimized applying QbD concepts. • The validation procedure demonstrated that this iELISA is accurate and precise. Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1007/s00253-022-12254-w.

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

“…ELISA methods can be improved by altering the assay parameters to increase the sensitivity or specificity, provide results faster, and boost the signal strength [ 30 ]. Typically, an optimization procedure is developed to improve the ratio between the signal of the positive and negative control samples, as well as the difference to the control conditions [ 31 ]. We optimized various parameters, such as reagent type and concentration, sample MRD, and incubation time in these two ELISA methods.…”

A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes

“…For fluorescence, microscopy analysis cells were analyzed under adherent conditions, following the protocol described by Rodríguez et al ( 2022 ).…”

Diseño factorial completo de experimentos para optimizar un ELISA que detecta anticuerpos anti-RBD del SARS-CoV-2

“…Sin embargo, el Diseño de Experimentos (DOE, por sus siglas en inglés) es un método útil para identificar y optimizar los factores significativos y lograr resultados adecuados utilizando la mínima cantidad posible de ensayos experimentales (Ahmed et al, 2022). Es un enfoque sistemático y basado en estadísticas donde se evalúan diferentes factores simultáneamente (Ray et al, 2009;Tsoi et al, 2014;Augustine et al, 2015;Rodríguez et al, 2022). La efectividad de este diseño radica en que, a diferencia de la práctica estándar de variar solo un factor a la vez, tanto los efectos principales de cada factor como las interacciones entre ellos pueden ser interpretados realizando menos experimentos en menos tiempo que el que requeriría el OFAT (Papaneophytou, 2019).…”